Fluorobenzenes
Research News and Information

Sunday, November 22, 2009

Efficacy of aggressive lipid controlling therapy for preventing saphenous vein graft disease.

30 Oct 2009 BACKGROUND: We assessed the efficacy of aggressive lipid controlling therapy (ALCT), which maintains low-density lipoprotein cholesterol (LDL-C) below to 80 mg/dL and LDL/high-density lipoprotein cholesterol (HDL-C) ratio less than 1.5 for ... Read more...

Effect of the HMG-CoA reductase inhibitor rosuvastatin on early chronic kidney injury in obese zucker rats fed with an atherogenic diet.

29 Sep 2009 The obese Zucker rat (OZR) spontaneously develops hyperlipidemia, insulin resistance, and microalbuminuria. In this study, the initial metabolic, functional, and glomerular pathology in young OZR fed with an atherogenic diet resembles the ... Read more...

[To treat or not to treat with statins patients with chronic heart failure?]

30 Aug 2009 Two clinical trials--CORONA and GISSI-HF--have been conducted to resolve uncertainties about the effects of statins in patients with chronic heart failure and justified suspicions that treatment with statins in these patients might be detrimental. ... Read more...

Latest indexed articles for 'Fluorobenzenes'

These are the very latest articles for this heading:

• Efficacy of aggressive lipid controlling therapy for preventing saphenous vein graft disease. 30 Oct 2009
• Effects of a 3-month course of rosuvastatin in patients with systemic lupus erythematosus. 29 Sep 2009
• Effect of the HMG-CoA reductase inhibitor rosuvastatin on early chronic kidney injury in obese zucker rats fed with an atherogenic diet. 29 Sep 2009
• [To treat or not to treat with statins patients with chronic heart failure?] 30 Aug 2009
• Most would fail to benefit from JUPITER Intervention. 16 Aug 2009
• Disappointing recent cholesterol-lowering drug trials: is it not time for a full reappraisal of the cholesterol theory? 15 Aug 2009
• [Significance of determination of lipid-oxidizing catalytic antibodies in patients with ischemic heart diseases] 30 Jul 2009
• Severe HIV-associated hypertriglyceridaemia treated with rosuvastatin plus omega-3 fatty acids. 30 Jul 2009
• Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins? 30 Jul 2009
• Alternate day dosing of rosuvastatin: potential usefulness in statin-intolerant patients. 30 Jul 2009
• Rosuvastatin for cardiovascular prevention: too many uncertainties. 30 Jul 2009
• Interactions of serotonin (5-HT)2 receptor-targeting ligands and nicotine: locomotor activity studies in rats. 30 Jul 2009
• Ion-pairing high-performance liquid chromatography determination of amitrole in apple after solid-phase extraction and precolumn derivatization. 24 Jul 2009
• Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat. 22 Jul 2009
• Statins and angiogenesis: is it about connections? 14 Jul 2009
• Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial. 2 Jul 2009
• Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial. 2 Jul 2009
• Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial. 2 Jul 2009
• Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial. 2 Jul 2009
• Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial. 2 Jul 2009

See a longer list of these articles.

Technical information about 'Fluorobenzenes'

Registry Number: 0

Descriptor UI: D005464

Alternative terms: Fluorobenzenes;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D02.455.526.510.432;

History Note: 74